Louise Convery, DO
Internal Medicine · Des Moines, IANPI 1699728287
Payments from drug & device makers
Across 519 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- Pfizer$983
- AstraZeneca$923
- Johnson & Johnson$923
- AbbVie$758
- Lilly USA, LLC$519
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,10296%
- Education$3764%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 73 | $1,210 |
| Pfizer | 70 | $983 |
| AstraZeneca | 46 | $923 |
| Johnson & Johnson | 63 | $923 |
| AbbVie(2 entities) | 48 | $758 |
| Lilly USA, LLC | 34 | $519 |
| Novo Nordisk | 30 | $384 |
| Amgen | 19 | $307 |
| Astellas Pharma US Inc | 10 | $282 |
| Actelion Pharmaceuticals US, Inc. | 5 | $239 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $235 |
| Bayer | 12 | $224 |
| Merck | 13 | $187 |
| Sanofi-aventis U.S. LLC | 9 | $182 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $139 |
| Mylan Specialty L.p. | 9 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $132 |
| GSK | 8 | $126 |
| Sunovion Pharmaceuticals Inc. | 9 | $106 |
| Abbott | 6 | $97 |
| E.r. Squibb & Sons, L.L.C. | 6 | $91 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 1 | $31 |
| Novartis | 2 | $27 |
| Ironwood Pharmaceuticals, Inc | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Cranial Technologies, Inc | 1 | $20 |
| Medtronic | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Biogen | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
| Insulet Corporation | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Boston Scientific | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $11 |
How this compares
$8,479 in reported general payments places this provider in the 95th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 61 | $72,001 |
| OzempicSemaglutide | 52 | $64,859 |
| JardianceEmpagliflozin | 89 | $61,516 |
| JanuviaSitagliptin Phosphate | 57 | $48,791 |
| EliquisApixaban | 37 | $32,282 |
| FarxigaDapagliflozin Propanediol | 43 | $32,185 |
| XareltoRivaroxaban | 34 | $28,113 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $13,284 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $12,268 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 37 | $8,803 |
| LevemirInsulin Detemir | 28 | $8,522 |
| Spiriva RespimatTiotropium Bromide | 15 | $7,770 |
| InvokanaCanagliflozin | 13 | $7,573 |
| Levemir FlexpenInsulin Detemir | 24 | $7,242 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $1,210 | $75,572117 claims |
| Novo NordiskOzempic, Levemir | $384 | $73,38180 claims |
| Lilly USA, LLCTrulicity | $519 | $72,00161 claims |
| MerckJanuvia | $187 | $48,79157 claims |
| AstraZenecaFarxiga, Symbicort | $923 | $39,18871 claims |
| Johnson & JohnsonXarelto, Invokana | $923 | $35,68747 claims |
| PfizerEliquis | $983 | $32,28237 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $126 | $13,20928 claims |
| Astellas Pharma US IncMyrbetriq | $282 | $5,61613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Des Moines
- Ryan TomlinsonDes Moines$209K
- Todd JensenDes Moines$9K
- Leatrice OlsonDes Moines$9K
- Laura KerseyDes Moines$8K
- Anthonia IjeliDes Moines$7K
- Omar JaradatDes Moines$4K
- Garrett WiltDes Moines$4K
- Kyle ClayDes Moines$3K
- Tyler MummDes Moines$2K
- Justin BergerDes Moines$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.